PMID- 35086855
OWN - NLM
STAT- MEDLINE
DCOM- 20220418
LR  - 20220822
IS  - 1554-6179 (Electronic)
IS  - 1539-4182 (Print)
IS  - 1539-4182 (Linking)
VI  - 20
IP  - 1
DP  - 2022 Mar
TI  - ST Segment Elevation Myocardial Infarction in the COVID-19 Era: Appraisal of the 
      Evidence.
PG  - 52-60
LID - 10.3121/cmr.2021.1707 [doi]
AB  - The COVID-19 pandemic continues to present a public health challenge and has had 
      a significant impact on the presentation, time-dependent management, and clinical 
      outcomes of ST elevation myocardial infarction (STEMI). Patients with COVID-19 
      and pre-disposing cardiovascular risk factors like hypertension, hyperlipidemia, 
      and diabetes mellitus are at a higher risk of developing STEMI, and global trends 
      have highlighted delayed management of STEMI, which may contribute to worse 
      clinical outcomes. Prolonged time to intervention has also resulted in an 
      increased rate of no reflow, which is an independent risk factor for worse 
      outcomes in these patients. Timely primary percutaneous coronary intervention 
      (PCI) remains standard of care for STEMI and can be attained within the 
      recommended 90 minutes timeline from hospital presentation. A coordinated, safe, 
      standardized, algorithmic approach among emergency medical services, emergency 
      departments, and cardiac catheterization laboratory is needed to ensure optimal 
      patient outcome during and after the COVID-19 pandemic. The focus of this case 
      report is to highlight the challenges of PCI for ST elevation myocardial 
      infarction in the COVID-19 era.
CI  - (c) 2022 Marshfield Clinic Health System.
FAU - Nwaedozie, Somto
AU  - Nwaedozie S
AD  - Department of Internal Medicine, Marshfield Clinic, Marshfield, Wisconsin USA 
      nwaedozie.somto@marshfieldclinic.org.
FAU - Rezkalla, Shereif H
AU  - Rezkalla SH
AD  - Department of Cardiology, Marshfield Clinic, Marshfield, Wisconsin USA.
AD  - Adjunct Professor of Medicine, University of Wisconsin, Madison, Wisconsin, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220127
PL  - United States
TA  - Clin Med Res
JT  - Clinical medicine & research
JID - 101175887
SB  - IM
MH  - *COVID-19
MH  - Humans
MH  - Pandemics
MH  - *Percutaneous Coronary Intervention/adverse effects/methods
MH  - Risk Factors
MH  - *ST Elevation Myocardial Infarction/complications/diagnosis/therapy
MH  - Treatment Outcome
PMC - PMC9390854
OTO - NOTNLM
OT  - COVID-19
OT  - No reflow
OT  - PCI
OT  - Pandemic
OT  - STEMI
EDAT- 2022/01/29 06:00
MHDA- 2022/04/19 06:00
PMCR- 2022/03/01
CRDT- 2022/01/28 05:51
PHST- 2021/07/12 00:00 [received]
PHST- 2021/11/10 00:00 [accepted]
PHST- 2022/01/29 06:00 [pubmed]
PHST- 2022/04/19 06:00 [medline]
PHST- 2022/01/28 05:51 [entrez]
PHST- 2022/03/01 00:00 [pmc-release]
AID - cmr.2021.1707 [pii]
AID - 10.3121/cmr.2021.1707 [doi]
PST - ppublish
SO  - Clin Med Res. 2022 Mar;20(1):52-60. doi: 10.3121/cmr.2021.1707. Epub 2022 Jan 27.